Dr. Shahab Ghafghazi, MD

Dr. Ghafghazi practices at Jewish Hospital and St Mary's Healthcare - HOPD in Louisville, Kentucky.

Dr. Ghafghazi's NPI, 1316195274, was assigned on September 4, 2008. Dr. Ghafghazi holds Kentucky license 44594.

Dr. Ghafghazi's primary practice is Jewish Hospital and St Mary's Healthcare - HOPD, at 200 Abraham Flexner Way, Louisville, KY 40202.

Dr. Ghafghazi's primary practice is Jewish Hospital and St Mary's Healthcare - HOPD in Louisville, Kentucky. Dr. Ghafghazi is also affiliated with UofL Health - Jewish Hospital. The medical group on file is UofL Physicians, Radiology. Dmand AI also links Dr. Ghafghazi to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ghafghazi practices, 5 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Ghafghazi's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Ghafghazi is licensed in Kentucky.

CMS data shows 1,597 Medicare services from Dr. Ghafghazi across 18 procedure codes in 2024, for 848 Medicare patients. Medicare paid $58,965 for them.

CMS counts 848 Medicare patients who saw Dr. Ghafghazi in 2024. The largest group is 65 to 74, with 353 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 27% are also on Medicaid. Their average risk score is 2.28, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ghafghazi's median patient age at 71, with 51% women.

In 2024, Dr. Ghafghazi wrote 1,538 Medicare Part D claims for 216 patients. 79% of them were for generic drugs. CMS names the drug for 1,406 of them, across 34 drugs with 11 or more claims each, at $295,785 in total drug cost. In 2023, CMS named 1,721 claims across 33 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Ghafghazi for performance year 2024, reported as part of a group. Dr. Ghafghazi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 47 papers to Dr. Ghafghazi, published from 2015 to 2025. 2021 was the busiest year, with 8. The most frequent topics are Heart Failure, Stem Cell Transplantation and Myocardial Infarction. Dr. Ghafghazi has published most often in Glob Cardiol Sci Pract. Dr. Ghafghazi's most frequent co-authors are Roberto Bolli, MD, David Douglas Berg, MD and Erin Ann Bohula, MD.

Dmand AI links Dr. Ghafghazi to 1 clinical trial. Conditions studied include Myocardial Infarction and Infarction.

CMS Open Payments shows 94 general payments to Dr. Ghafghazi from 21 drug and device companies from 2018 to 2025. Travel and lodging make up the largest share, 60% of the total. Abbott Laboratories paid the most, $3,796.